Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06666413

China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD

This is a single group, 52-week treatment, Phase 4, open-label, single-arm study to assess the safety and efficacy of avalglucosidase alfa IV infusion in male and female Chinese participants with IOPD who are treatment-naïve or were previously treated with ERT.

Study details include:

* The study duration: total study duration is approximately 64 weeks.

* Screening period of up to 8 weeks * Treatment period of 52 weeks * Follow-up period of 4 weeks. (if the participant enrolls in another study or receives commercially available ERT, the follow-up period may be reduced from 4 to 2 weeks) * The number of visits will be 30, including 29 site visits and 1 phone call follow-up visit.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Glycogen Storage Disease Type II Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Carbohydrate Metabolism, Inborn Errors Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Glycogen Storage Disease Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Nutritional and Metabolic Diseases Pompe's Disease

Age range

Up to 17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Investigational Site Number: 1560001

Shanghai, 200127, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be <18 years of age, at the time of signing the informed consent.
  • Participants have documented onset of Pompe disease symptoms before 12 months of age (corrected for gestation if born before 40 weeks); and diagnosis of IOPD is confirmed by GAA enzyme deficiency from any tissue source and GAA gene pathogenic mutations.
  • Participants must have documented cardiomyopathy at the time of diagnosis.
  • Contraceptive use should be consistent with local regulations Participant's parent/legally authorized representative (LAR) must be capable of giving signed informed consent.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

  • Participants with major congenital abnormality that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival.
  • Participants with clinically significant organic disease (with the exception of symptoms relating to Pompe disease).
  • Participants who have received an ERT other than alglucosidase alfa or avalglucosidase alfa, or any other treatment for Pompe disease, including gene therapy prior to the enrollment.
  • Participants who have received alglucosidase alfa or avalglucosidase alfa less than 1 week prior to the first dose of avalglucosidase alfa given as IMP Participants who are anticipated to take prohibited therapy (ie, any other treatment for Pompe disease) during this study.
  • Participants who have taken other investigational drugs (not Pompe disease specific) within 30 days or 5 elimination half-lives in blood of that drug before enrollment, whichever is longer, or are anticipated to take any other concurrent investigational treatments.
  • Participants not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Avalglucosidase alfa

Drug

Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion

Other names: GZ402666, Nexviazyme

Primary outcomes

  1. Incidence of AEs, SAEs, AESIs including IARs during the TE period

    Time frame: From baseline to Week 56

  2. Abnormality in clinical laboratory, vital signs, and ECG parameters during the TE period

    Time frame: From baseline to Week 56

Secondary outcomes

  1. Proportion of participants who are alive and free of invasive ventilation at Week 52

    Time frame: At Week 52

  2. Change from baseline to Week 52 in LVM Z score evaluated by echocardiography

    Time frame: From baseline to Week 52

  3. The absolute change in body growth Z scores from baseline to Week 52

    Time frame: From baseline to Week 52

  4. The percentiles of the body growth Z scores changes from baseline to Week 52

    Time frame: From baseline to Week 52

  5. Change from baseline to Week 52 in distance walked during six-minute walk test (6MWT) (in applicable participants)

    Time frame: From baseline to Week 52

  6. Change from baseline to Week 52 in quick motor function test (QMFT) score (in applicable participants)

    Time frame: From baseline to Week 52

  7. Number of motor development milestones achieved as evaluated by Motor Milestone Checklist at Week 52

    Time frame: At Week 52

Study contacts

Contact information is provided by the study sponsor or research team.

Trial Transparency email recommended (Toll free for US & Canada)

CONTACT

[email protected]

800-633-1610 ext. option 6

Sponsors and collaborators

Lead sponsor

Genzyme, a Sanofi Company

Industry

Registry information

Official study title

A Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Avalglucosidase Alfa in Chinese Participants With Infantile-onset Pompe Disease (IOPD)

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Oct 30, 2024
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.